These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22305694)

  • 21. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
    ; Mehta SR; Bassand JP; Chrolavicius S; Diaz R; Eikelboom JW; Fox KA; Granger CB; Jolly S; Joyner CD; Rupprecht HJ; Widimsky P; Afzal R; Pogue J; Yusuf S
    N Engl J Med; 2010 Sep; 363(10):930-42. PubMed ID: 20818903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
    Rodondi N; Bauer DC
    Am J Med; 2004 Oct; 117(7):528-30. PubMed ID: 15464713
    [No Abstract]   [Full Text] [Related]  

  • 23. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Gianetti J; Gensini G; De Caterina R
    Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicare physician payment reform and the utilization of cardiovascular procedures.
    Okunade AA; Miles AP
    J Health Soc Policy; 1999; 11(1):37-52. PubMed ID: 10538429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietary salt reduction and cardiovascular disease.
    Nair M; Prabhakaran D
    Natl Med J India; 2010; 23(6):352-3. PubMed ID: 21561048
    [No Abstract]   [Full Text] [Related]  

  • 27. [The CURRENT-OASIS 7 study].
    Ardissino D; Patti G; Magnani G; Mantovani F; Demola MA
    G Ital Cardiol (Rome); 2011 Mar; 12(3):167-71. PubMed ID: 21560471
    [No Abstract]   [Full Text] [Related]  

  • 28. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
    Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
    Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
    Saini SD; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.
    Chen J; Shi C; Mahoney EM; Dunn ES; Rinfret S; Caro JJ; O'Brien J; El-Hadi W; Bhatt DL; Topol EJ; Cohen DJ
    Can J Cardiol; 2011; 27(2):222-31. PubMed ID: 21459271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fame comes at a cost: a Canadian analysis of procedural costs in use of pressure wire to guide multivessel percutaneous coronary intervention.
    Hoole SP; Seddon MD; Poulter RS; Mancini GB; Wood DA; Saw J
    Can J Cardiol; 2011; 27(2):262.e1-2. PubMed ID: 21459275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An ounce of prevention.
    Fuster V
    Nat Rev Cardiol; 2009 Sep; 6(9):553-4. PubMed ID: 19696772
    [No Abstract]   [Full Text] [Related]  

  • 34. Common sense, dollars and cents, and drug-eluting stents.
    Vaitkus PT
    J Am Coll Cardiol; 2006 Jul; 48(2):268-9. PubMed ID: 16843173
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical and economic outcomes after introduction of drug-eluting stents.
    Rihal CS; Ryan JL; Singh M; Lennon RJ; Bresnahan JF; Liesinger JT; Gersh BJ; Ting HH; Holmes DR; Long KH
    Am J Manag Care; 2010 Aug; 16(8):580-7. PubMed ID: 20712391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Other studies show aspirin use is high.
    Brown J
    PLoS Med; 2006 Feb; 3(2):e110; author reply e109. PubMed ID: 16492077
    [No Abstract]   [Full Text] [Related]  

  • 38. Too much angioplasty.
    Malhotra A
    BMJ; 2013 Sep; 347():f5741. PubMed ID: 24065554
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiac rehabilitation. Increased referrals can decrease mortality, morbidity and costs.
    Privette T
    Adv Nurse Pract; 2002 Jan; 10(1):79-80. PubMed ID: 12420518
    [No Abstract]   [Full Text] [Related]  

  • 40. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.